Cognex Corporation
NASDAQ:CGNXHardware, Equipment & Parts
-$0.64 today
- Market cap
- $8.27B
- Beta
- 1.51
- P/E (TTM)
- 75.7
- EPS (TTM)
- $0.86
- Dividend yield
- 0.52%
Volume 1.61M
Average 2.14M
CGNX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Cognex CorporationNASDAQ: CGNX
Research & Development · Q3 FY2026 · quarter ended Oct 2026
Research & development dips below year-ago levels
Q3 FY2026 research & development of $33.9M fell 3.4% year over year, behind the +2.9% change in trailing-twelve-month research & development. Sequentially, it rose 4.6% from the prior quarter. Over 3 fiscal years it compounded at -0.5% a year.
Context
- Research & development amounted to 14.0% of revenue in FY2025, down 1.3 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -3.4% toward the trailing-twelve-month pace of +2.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 138.97M USD
- Year-over-year change
- -0.6%
- 4-year CAGR
- +0.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 138.97M | -0.6% |
| FY2024 | 2024-12-31 | 139.82M | +0.3% |
| FY2023 | 2023-12-31 | 139.4M | -1.2% |
| FY2022 | 2022-12-31 | 141.13M | +4.3% |
| FY2021 | 2021-12-31 | 135.37M | — |
Research & Development vs competitors
How CGNX compares with its peers on the latest reported figures
- CGNX's LTM Oct 2026 research & development of $139.37M is the 2nd highest of the 5 companies compared; the peer median is $112.52M.
- Its year-over-year change of +2.9% is the 2nd highest of 5, against a peer median of -1.2%.
- Research & development amounts to 12.4% of revenue for CGNX, versus a peer median of 9.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $622M | +8.4% | +1.3% | 10.6% | |
| LTM Oct 2026 | $139.37M | +2.9% | -0.5% | 12.4% | |
| LTM Sep 2026 | $128.6M | -7.1% | -10.9% | 3.3% | |
| LTM Oct 2026 | $96.43M | -1.5% | +3.6% | 8.9% | |
| LTM Mar 2026 | $38.76M | -0.9% | +1.4% | 2494.3% | |
| Peer median (excluding CGNX) | $112.52M | -1.2% | +1.4% | 9.8% | |
Competitors are the stored peer set for CGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.04B | 1.01B | 837.55M | 914.52M | 994.36M |
| Cost of Revenue | 277.27M | 284.19M | 236.31M | 288.72M | 328.97M |
| Gross Profit | 759.83M | 721.91M | 601.24M | 625.79M | 665.39M |
| Gross Margin | 73.3% | 71.8% | 71.8% | 68.4% | 66.9% |
| Research & Development | 135.37M | 141.13M | 139.4M | 139.82M | 138.97M |
| Selling, General & Admin | 309.35M | 312.11M | 339.14M | 370.91M | 363.86M |
| Operating Expenses | 444.73M | 475.68M | 470.54M | 510.73M | 502.83M |
| Depreciation & Amortization | 20.28M | 19.62M | 21.88M | 32.69M | 30.79M |
| EBITDA | 339.18M | 288.29M | 144.58M | 164.18M | 213.6M |
| EBITDA Margin | 32.7% | 28.7% | 17.3% | 18.0% | 21.5% |
| Operating Income | 315.1M | 246.23M | 130.7M | 115.07M | 162.57M |
| Operating Margin | 30.4% | 24.5% | 15.6% | 12.6% | 16.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 3.8M | 4.47M | 4.65M | 16.42M | 20.24M |
| Income Before Tax | 318.9M | 250.7M | 135.35M | 131.49M | 182.8M |
| Pre-Tax Margin | 30.7% | 24.9% | 16.2% | 14.4% | 18.4% |
| Income Tax Expense | 39.02M | 35.17M | 22.11M | 25.32M | 68.36M |
| Net Income | 279.88M | 215.53M | 113.23M | 106.17M | 114.44M |
| Net Margin | 27.0% | 21.4% | 13.5% | 11.6% | 11.5% |
| EPS (Basic) | 1.59 | 1.24 | 0.66 | 0.62 | 0.68 |
| EPS (Diluted) | 1.56 | 1.23 | 0.65 | 0.62 | 0.68 |
| Weighted Avg Shares | 176.46M | 173.41M | 172.25M | 171.44M | 168.05M |
| Weighted Avg Shares (Diluted) | 179.92M | 174.87M | 173.4M | 172.61M | 169.37M |
Cognex Corporation
NASDAQ:CGNX
Intrinsic Alpha fair value
Locked
Current Price
$49.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.